GSK licensed rights to GSK'227 outside China, Hong Kong, Macao, and Taiwan in December 2023 for $185 million upfront and another $1.525 billion is potential milestone payments. A few weeks earlier ...
Also this week, GSK bolstered its oncology pipeline by taking an option on an antibody-drug conjugate (ADC) from Chinese biotech Duality Biologics outside mainland China, Hong Kong, and Macau.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback